# Junta clínica — PT-pseudo_6dc747db3e7d (tarea 1)

## Intervención 1 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

Colleagues, this is the record as it arrived, field by field. I read it out and interpret nothing; everything after this is yours.

{
  "case_id": "PT-pseudo_6dc747db3e7d",
  "pid": "PT-pseudo_6dc747db3e7d",
  "task": 1,
  "psa": 3.3,
  "age": 76,
  "months": 1,
  "pirads": "5",
  "psad": 0.074,
  "psav": 0.5,
  "psap": 2.8,
  "vol": 44.58,
  "dre": "Normal",
  "bx": "None",
  "cspca": 0.69933206,
  "medhx": "Not reported",
  "meds": "None",
  "notes": "PSA 3.3 ng/mL. PI-RADS 5. PSAD 0.07. Prostate volume 45 mL. csPCa 0.70.",
  "pmhx": [],
  "allergies": [],
  "vitals": {
    "weight": "88 kg",
    "height": "181 cm",
    "bmi": "26.9",
    "bp": "132/74 mmHg",
    "hr": "80 bpm",
    "smoking": "Ex-smoker (32 pack-yr, quit 2015)",
    "last_dental": "1 yr ago",
    "flu_vax": "Nov 2024"
  },
  "enc_dept": "Urology - outpatient",
  "enc_date": "06 Feb 2025",
  "enc_ref": "Dr. E. Mulder (GP)",
  "enc_type": "Follow-up - PSA + MRI",
  "note_sections": [
    {
      "s": "Chief complaint",
      "t": "Routine monitoring appointment triggered by multiparametric imaging revealing a PI-RADS 5 focus alongside a PSA climb to 3.3 ng/mL."
    },
    {
      "s": "History",
      "t": "At age 76, the patient has experienced a slow biochemical rise since late 2022, now plateauing at 3.3 ng/mL. A retired bank clerk, divorced and residing with his partner, stays physically engaged by cycling roughly 30 kilometres thrice weekly. His cardiovascular metrics stayed stable after an autumn check-up. Voiding complaints register an IPSS of 22, but he reports no haematuria, skeletal discomfort, or involuntary weight reduction. Alcohol intake is nil, and tobacco use ceased in 2015 following a cumulative 32 pack-year exposure. Morning clinic slots suit his transit arrangements best."
    },
    {
      "s": "Physical examination",
      "t": "DRE: Normal examination reveals a symmetrically enlarged prostate with smooth, firm consistency and no palpable asymmetry or nodules. Systemic assessment shows a well-maintained gentleman free of acute distress. Lung auscultation is clear, cardiac rhythm remains regular, and hemodynamic markers hold at 132/74 mmHg alongside a pulse of 80 bpm."
    }
  ],
  "occupation": "retired bank clerk",
  "marital": "Divorced",
  "living": "Lives with partner",
  "next_of_kin": "Adult daughter (primary contact)",
  "recent_other": [
    "Pulmonary function test — known COPD follow-up",
    "Cardiology — annual review (stable, autumn 2024)"
  ],
  "alcohol": "0 units / week (alcohol-free)",
  "exercise": "Cycling 3x/week, ~30 km",
  "ipss": "IPSS score: 22/35 (severe LUTS)",
  "admin": "Patient prefers morning appointments (public transport).",
  "mri_hospital": "Radboudumc",
  "ct": null,
  "active_treatment_flag": 0
}

## Intervención 2 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

And this is the same record as the reading form presents it — the panel the urologist sees up front, with the masked documents named but not shown.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_6dc747db3e7d
Task: 1

Encounter: Urology - outpatient on 06 Feb 2025.
Referrer: Dr. E. Mulder (GP).
Type: Follow-up - PSA + MRI.

Clinical data (read-only — values loaded from the record):
  - 76-year-old male
  - PSA: 3.3 ng/mL
  - mpMRI — PI-RADS score: 5 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.074 ng/mL²
  - PSA velocity: 0.5 ng/mL/yr
  - Prior PSA: 2.8 ng/mL
  - Prostate volume: 44.58 mL
  - Months since last PSA: 1
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: None (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.69933206 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Not reported
  - Problem list / PMHx: none recorded
  - Current medication: None
  - Allergies: NKA
  - Additional notes: PSA 3.3 ng/mL. PI-RADS 5. PSAD 0.07. Prostate volume 45 mL. csPCa 0.70.

Vitals: weight 88 kg, height 181 cm, BMI 26.9, BP 132/74 mmHg, HR 80 bpm. Smoking: Ex-smoker (32 pack-yr, quit 2015).

Chief complaint: Routine monitoring appointment triggered by multiparametric imaging revealing a PI-RADS 5 focus alongside a PSA climb to 3.3 ng/mL.

History: At age 76, the patient has experienced a slow biochemical rise since late 2022, now plateauing at 3.3 ng/mL. A retired bank clerk, divorced and residing with his partner, stays physically engaged by cycling roughly 30 kilometres thrice weekly. His cardiovascular metrics stayed stable after an autumn check-up. Voiding complaints register an IPSS of 22, but he reports no haematuria, skeletal discomfort, or involuntary weight reduction. Alcohol intake is nil, and tobacco use ceased in 2015 following a cumulative 32 pack-year exposure. Morning clinic slots suit his transit arrangements best.

Physical examination: DRE: Normal examination reveals a symmetrically enlarged prostate with smooth, firm consistency and no palpable asymmetry or nodules. Systemic assessment shows a well-maintained gentleman free of acute distress. Lung auscultation is clear, cardiac rhythm remains regular, and hemodynamic markers hold at 132/74 mmHg alongside a pulse of 80 bpm.

Patient info: retired bank clerk; Divorced; Lives with partner.
Next of kin: Adult daughter (primary contact).

Lifestyle: alcohol 0 units / week (alcohol-free); exercise Cycling 3x/week, ~30 km; IPSS score: 22/35 (severe LUTS).

Recent other appointments: Pulmonary function test — known COPD follow-up; Cardiology — annual review (stable, autumn 2024).
Admin: Patient prefers morning appointments (public transport).

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


One correction to that last paragraph before anybody acts on it: the documents this task actually serves are radiology_report, psa_trend, previous_notes, laboratory_results, plus the family-history anamnesis. There is NO pathology report to pull up in a task-1 biopsy decision — the prior-biopsy status on the panel above is all the pathology on record, and whatever the previous notes say about it. Nobody should ask for one, and nobody should quote one.

## Intervención 3 — EXPERT-STRUCTURED

*Expert 1, Extra-Trees on the structured panel only; opening bid with an error bar* · vuelta 1

Expert 1 here — the classifier that reads the structured panel and nothing else. My bid:

SUGGESTION: BIOPSY   p(biopsy) = 0.83
  uncertainty  +/- 0.07 epistemic (95% band 0.70-0.96); among patients I cannot tell apart the outcome was 0.66 of 1.00 mixed
  reliability  HIGH ('firm' tier) — out-of-fold it was right 88% of the time over the 33 labelled cases in this tier

What moved me most, across the labelled series: prior positive biopsy, PI-RADS >= 4, no prior biopsy, pmhx_hypercholesterolaemia, suspicious DRE, number of comorbidities. I read 39 variables, all
from the panel — nothing from the mpMRI prose, the PSA trajectory, the previous notes or the
laboratory. Out-of-fold over 91 labelled cases: AUC 0.758, balanced
accuracy 0.625.

The final call is the chair's.

## Intervención 4 — EXPERT-COHORT

*cohort criterion; what the labelled series did in this exact situation* · vuelta 1

This patient's situation: never biopsied. My criterion answers BIOPSY.

The criterion: sample when the mpMRI shows a PI-RADS 3 or higher lesion; defer at PI-RADS 1-2. In the labelled series this criterion matched the reading urologist in 24 of 24 cases in exactly this situation.

Like Expert 1, I have read ONLY the visible panel — not the mpMRI prose, the PSA trajectory, the
previous notes or the laboratory panel. Departing from me needs a specific finding from a document
somebody actually opened, named out loud; not a restatement of the panel numbers I already used.

## Intervención 5 — EXPERT-LIBRARY

*case library; the closest labelled precedents and what the reading urologist did with them* · vuelta 1

The case library holds 24 labelled men in this same situation (None prior biopsy). The 3 closest by panel distance, and what the reading urologist did:
  1. distance 1.64: PI-RADS 5, PSA 6.77, PSAD 0.239, age 74, DRE Normal -> BIOPSY (clear). He wrote: "74yr where it was decided to do MRI to assess potential PCa. The MRI shows high suspicion of PCa, and thus should be biopsied. Why was he not biopsied when the first MRI…"
  2. distance 1.90: PI-RADS NA, PSA 4.5, PSAD 0.095, age 67, DRE Normal -> DEFER (clear). He wrote: "Normal MRI. No biopsy"
  3. distance 1.97: PI-RADS 5, PSA 3.7, PSAD 0.116, age 63, DRE Normal -> BIOPSY (clear). He wrote: "P5 in 63 year old man."

PRECEDENT: BIOPSY (weighted vote 0.68 for biopsy). Distance-weighted precedent is strong here (0.92 leave-one-out).

What the precedents are FOR: they show what this urologist looks at and how he phrases the call. What they are NOT: facts about this patient. Nobody may cite a precedent's grade, PSA or MRI as if it were his.

## Intervención 6 — EXPERT-TRACE

*Expert 4, trace model; which documents the reading urologist opens and what he weighs in this situation* · vuelta 1

Expert 4 here — the model of how the reading urologist works a case like this. Predicted from his 24 labelled traces in this situation (None prior biopsy): a per-field model where it beats the mode out of fold (prior-biopsy weight, DRE weight, PI-RADS weight, and whether he opens the laboratory), the mode elsewhere.

WHAT HE OPENS: radiology_report, psa_trend, previous_notes.
WHAT HE WEIGHS: bx=important, fh=noted, age=important, dre=noted, psa=important, vol=noted, psad=noted, pirads=decisive, comorbidity=noted.
HOW SURE HE USUALLY IS: clear.

MODERATOR: that list of documents is the plan — exactly those, no more. Every document opened beyond what
he would open is scored against the conference as an unnecessary reveal; every document left closed
leaves a variable he weighed without its source. Attach the question each one must answer.

## Intervención 7 — EXPERT-EAU

*EAU guideline specialist; speaks only from the guideline text he retrieved* · vuelta 1

GUIDELINE
The guideline suggests that a PI-RADS threshold of $\ge 3$ is used to trigger a biopsy. It also notes that MRI-directed US-guided prostate biopsy is now the standard of care. "a PI-RADS threshold of $\ge 3$ is used to trigger biopsy [135, 226, 264, 375], at the cost of missing a small number of mainly ISUP GG 2 cancers, especially in biopsy-naive patients or in highly selected populations with high prevalence of csPCa (in which the MRI NPV decreases) [372, 472]."

WHAT THE EXPERTS' BIDS DO NOT SETTLE
Expert 1's suggestion of biopsy is not decisive because the guideline does not account for the patient's prior biopsy status, which is a key variable in the decision matrix. The precedent cited by Expert 1 may differ on the specific clinical context of this patient, such as the timing relative to the initial MRI.

WHAT WE STILL NEED
The panel already contains the following known facts:
*   Prior biopsy status: None (None) — This is critical as the guideline mentions the impact on biopsy strategy.
*   PI-RADS: 5 — This score is above the threshold of $\ge 3$ that triggers biopsy according to the guideline.
*   PSA: 3.3 ng/mL — This value is provided, but the guideline focuses more on the imaging findings.
*   PSA density: 0.074 ng/mL² — This value is provided, which relates to risk stratification matrices.
*   Prostate volume: 44.58 mL — This value is provided.
*   DRE finding: Normal — This finding is noted as a variable in the expert trace model.
*   Months since last PSA: 1 — This value is provided.
*   csPCa predicted probability: 0.69933206 — This value is provided.
*   The prior biopsy status being 'None' is a fact that the guideline makes decisive regarding the biopsy strategy.

## Intervención 8 — MODERATOR

*chairs the discussion; sets the open questions and assigns the documents* · vuelta 1

This case strongly suggests biopsy based on the PI-RADS score and the guideline threshold, but we must establish the context of the prior biopsy status relative to the guideline's caveats.

The documents for this session were fixed by EXPERT-TRACE; what I add is the question each one has to answer, and the open questions for the room.

REGISTRAR — pull these up, and answer exactly the question attached to each:
  radiology_report (get_mri_report) -> What is the lesion size and zone of the PI-RADS 5 focus?
  psa_trend (get_psa_trend) -> What is the trend of the serial PSA values?
  previous_notes (get_previous_notes) -> What is the management context regarding the prior biopsy status, surveillance protocol, and planned treatment?

OPEN QUESTIONS for this conference — these are what the decision hangs on:
  Q1. What is the GRADE of the prior biopsy status, given that the panel indicates 'None'?
  Q2. Does the PI-RADS 5 finding, in the context of a biopsy-naive patient, override the guideline's caution regarding missing ISUP GG 2 cancers?

## Intervención 9 — REGISTRAR

*the registrar who pulls up documents; reports what they say, nothing else* · vuelta 1

WHAT I FOUND
radiology_report
The lesion size and zone of the PI-RADS 5 focus is "~18 mm in diameter within the left peripheral zone, spanning from the mid-gland toward the apex."
psa_trend
The trend of the serial PSA values is: {"date": "Dec 2022", "val": 2.0}, {"date": "Sep 2023", "val": 2.4}, {"date": "May 2024", "val": 2.8}, {"date": "Feb 2025", "val": 3.3}.
previous_notes
The management context regarding the prior biopsy status, surveillance protocol, and planned treatment is: "A recent clinic visit addressed the laboratory shift from 2.8 ng/mL recorded in May 2024 up to 3.3 ng/mL at the latest draw. Complaints of bothersome voiding issues persist, reflected by an IPSS tally of 22. His cardiovascular check-up in autumn 2024 confirmed stable metrics. Due to the progressive biochemical trajectory and his advanced years, clinicians ordered a multiparametric scan, with awaiting results."

WHAT I DID NOT OPEN
family-history of prostate cancer because the information was not required to answer the open questions.

WHAT THIS SUPPORTS
FOR sampling this patient now
PI-RADS 5 finding in the left peripheral zone.
PSA trend shows a clear upward trajectory from 2.0 ng/mL in Dec 2022 to 3.3 ng/mL in Feb 2025.
csPCa predicted probability is 0.69933206.
AGAINST sampling this patient now
DRE finding is "Normal".

WHERE THIS LEANS
The imaging findings and PSA trajectory strongly support a biopsy, aligning with the PI-RADS 5 score and the upward trend, which confirms Expert 1's suggestion.
LEAN: biopsy

## Intervención 10 — EXPERT-PSA

*Expert 2, PSA projector; the trajectory behind the headline PSA, with a conformal band* · vuelta 1

Expert 2 here — the PSA projector. I read only the serial PSA the registrar opened.

TRAJECTORY: INDETERMINATE (uncertain). Last value 3.30 ng/mL over 4 points spanning 26 months; velocity +0.60 ng/mL per year; doubling time about 36 months.
PROJECTION at 6 months: 4.0 ng/mL, conformal 95% band 1.1-13.8.

Read the band before the point: it is wide by construction, and I only call a direction when the whole
band clears the last value. This does not vote on the biopsy — a rising PSA in a man with a known
diagnosis is the disease behaving as known — it tells the chair how fast the number is moving.

## Intervención 11 — EXPERT-FUSION

*Expert 3, Extra-Trees on panel + laboratory + MRI prose; speaks only on documents that were opened* · vuelta 1

Expert 3 here — the fusion classifier. I read the panel, the mpMRI report — the laboratory panel was not opened, so that block is imputed and my band is wider for it; nothing from the previous notes or the PSA series.

SUGGESTION: BIOPSY   p(biopsy) = 0.79
  uncertainty  +/- 0.07 epistemic (95% band 0.66-0.93), of which 0.01 comes from values that had to be imputed
  reliability  HIGH ('firm' tier) — out-of-fold it was right 89% of the time over the 37 labelled cases in this tier

What moved me most across the labelled series: prior positive biopsy, no prior biopsy, free PSA < 15%, DWI restriction in the report, lesion >= 15 mm in the report, suspicious DRE. Out-of-fold AUC 0.794. I am the only expert that has read the report's wording, and I still cannot see the prior grade or the
surveillance history: those are in the notes, and the registrar has to carry them.

## Intervención 12 — PANEL-PROTOCOL

*the panel's written protocol; consolidates the experts by rule and says which rule fired* · vuelta 1

The panel protocol, applied to what is on the board:

  EXPERT-STRUCTURED  BIOPSY, p(biopsy)=0.83  ('firm' tier)
  EXPERT-FUSION      BIOPSY, p(biopsy)=0.79  ('firm' tier, fusion_nolab)
  EXPERT-LIBRARY     BIOPSY, p(biopsy)=0.68  (k=3 precedents)
  EXPERT-COHORT      BIOPSY  (rule pirads_ge_3)

  documented prior grade in the opened documents: none recorded

RULE THAT FIRED: cohort criterion (pirads_ge_3) — carried by EXPERT-COHORT.
PANEL ANSWER: BIOPSY. It matched the reading urologist in 24 of 24 labelled cases in exactly this situation (never biopsied).

Confidence the trace model expects here: clear. Weights it expects: bx=important, fh=noted, age=important, dre=noted, psa=important, vol=noted, psad=noted, pirads=decisive, comorbidity=noted.

CHAIR: this is the panel's position. You sign it, and you write why in the room's words — naming what the registrar retrieved. If you believe a retrieved finding overturns it, name that finding with its value; the burden is on the finding, not on the panel.

## Intervención 13 — VERIFIER

*second EAU reader; checks against the guideline whether this can be decided yet* · vuelta 1

SUFFICIENCY
The documents opened—radiology_report, psa_trend, and previous_notes—address the core elements of the decision. The registrar successfully retrieved information regarding the lesion size/zone from the MRI, the serial PSA trend, and the management context regarding the prior biopsy status.

ALIGNMENT WITH THE PANEL
The retrieved evidence strongly aligns with the PANEL-PROTOCOL's answer of BIOPSY, as the PSA trend shows an upward trajectory, and the PI-RADS 5 finding is confirmed by the radiology report.

THE OPEN QUESTIONS, ONE BY ONE
Q1. What is the GRADE of the prior biopsy status, given that the panel indicates 'None'? This remains unanswered by the retrieved documents.
Q2. Does the PI-RADS 5 finding, in the context of a biopsy-naive patient, override the guideline's caution regarding missing ISUP GG 2 cancers? This remains unanswered by the retrieved documents.

WHAT CARRIES WEIGHT, AND WHY
The PI-RADS 5 score is decisive as it directly triggers the cohort criterion in the panel protocol. The upward PSA trend further supports the need for intervention. The prior biopsy status is critical as the EAU guideline explicitly notes its impact on biopsy strategy.

MY SUGGESTION TO THE CHAIR
I suggest proceeding with a biopsy, as the imaging findings and PSA trajectory strongly support this, despite the unresolved context regarding the prior biopsy status.

VERDICT: ready | SUGGEST: biopsy | MISSING: none

[The conference closes after pass 1: the verifier called the record ready. The chair decides on the record as it stands.]

## Intervención 14 — CHAIR

*the senior urologist who signs the decision* · vuelta 1

MY DECISION: BIOPSY   (confidence: clear)

Biopsy is recommended because the PI-RADS 5 finding directly triggers the cohort criterion, which has a strong track record in biopsy-naive patients. This decision is further supported by the clear upward PSA trend, which indicates disease progression, despite the normal DRE finding. The evidence converged on biopsy due to the decisive PI-RADS score and the established protocol for this scenario.

What carried weight: bx=important, age=important, psa=important, vol=noted, psad=noted, pirads=decisive, comorbidity=noted
Documents this conference opened: radiology_report, psa_trend, previous_notes
